Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine in MG Thymectomy
NCT06436768Completed
- Sponsor
- Beijing Tongren Hospital
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Time to recovery of train-of-four stimulation ratio (TOFr) to 0.9 at 24 hours. Started Jun 2024; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT06436768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06436768.